Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ArriVent BioPharma, Inc. - Common Stock (NQ:AVBP)

30.38 +3.41 (+12.64%)
Streaming Delayed Price Updated: 12:14 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 435,827
Open 27.24
Bid (Size) 30.31 (100)
Ask (Size) 30.47 (100)
Prev. Close 26.97
Today's Range 27.00 - 30.50
52wk Range 16.10 - 32.14
Shares Outstanding 33,697,161
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ArriVent Posts Wider Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga

Performance

YTD
+46.1%
+46.1%
1 Month
+1.1%
+1.1%
3 Month
+30.8%
+30.8%
6 Month
+32.4%
+32.4%
1 Year
+51.6%
+51.6%

More News

Read More
News headline image
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside ↗
Via Benzinga
News headline image
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
Topics Economy
News headline image
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Via MarketBeat
Topics Initial Public Offering
News headline image
AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 ↗
Via InvestorPlace
News headline image
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗
Via Talk Markets
News headline image
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 ↗
Via InvestorPlace
News headline image
ArriVent BioPharma Reports First Quarter 2024 Financial Results
From ArriVent BioPharma, Inc.
Via GlobeNewswire
News headline image
ArriVent Appoints Kristine Peterson to its Board of Directors
From ArriVent BioPharma, Inc.
Via GlobeNewswire
News headline image
ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗
Via Benzinga
News headline image
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal ↗
Via Talk Markets
News headline image
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗
Via Benzinga
News headline image
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower ↗
Via Talk Markets
Topics Initial Public Offering
News headline image
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China ↗
Via Talk Markets
Topics Initial Public Offering

Frequently Asked Questions

Is ArriVent BioPharma, Inc. - Common Stock publicly traded?
Yes, ArriVent BioPharma, Inc. - Common Stock is publicly traded.
What exchange does ArriVent BioPharma, Inc. - Common Stock trade on?
ArriVent BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ArriVent BioPharma, Inc. - Common Stock?
The ticker symbol for ArriVent BioPharma, Inc. - Common Stock is AVBP on the Nasdaq Stock Market
What is the current price of ArriVent BioPharma, Inc. - Common Stock?
The current price of ArriVent BioPharma, Inc. - Common Stock is 30.38
When was ArriVent BioPharma, Inc. - Common Stock last traded?
The last trade of ArriVent BioPharma, Inc. - Common Stock was at 05/29/26 12:14 PM ET
What is the market capitalization of ArriVent BioPharma, Inc. - Common Stock?
The market capitalization of ArriVent BioPharma, Inc. - Common Stock is 1.02B
How many shares of ArriVent BioPharma, Inc. - Common Stock are outstanding?
ArriVent BioPharma, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.